Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
, a physician-scientist founded health and wellness company, today announced it has raised a total of $14.5 million , including a recently concluded $8 million Series A round supported by major shareholders Sororibus Capital and Biostack Ventures
Glucagon-like peptide-1 analogues exenatide and liraglutide exert inhibitory effect on the early phase of liver regeneration after partial hepatectomy in rats
GLP-1 microdosing occupies the space of adjunctive therapy, something added alongside standard treatment to improve outcomes
Recent research has demonstrated that copper dyshomeostasis was tightly associated with the development of depression by inducing oxidative stress and inflammatory responses
US$ 27.34
US$ 25.92
US$ 22.98
US$ 25.62
